Thus, we next evaluated whether FTY720 could modulate doxorubicin sensitivity of breast cancer cells, observing that doxorubicin-induced antitumor effects were markedly enhanced after FTY720-induced PP2A activation. The gene discussed is PTPA; the disease is breast carcinoma.